Empowered Funds LLC Acquires 23,228 Shares of Cencora, Inc. $COR

Empowered Funds LLC raised its holdings in Cencora, Inc. (NYSE:COR) by 154.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 38,293 shares of the company’s stock after buying an additional 23,228 shares during the period. Empowered Funds LLC’s holdings in Cencora were worth $12,029,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Apollon Wealth Management LLC raised its holdings in shares of Cencora by 0.5% in the 4th quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company’s stock worth $2,205,000 after acquiring an additional 30 shares during the last quarter. Accent Capital Management LLC boosted its stake in Cencora by 36.1% during the 4th quarter. Accent Capital Management LLC now owns 113 shares of the company’s stock valued at $38,000 after purchasing an additional 30 shares during the last quarter. MCF Advisors LLC boosted its stake in Cencora by 11.0% during the 4th quarter. MCF Advisors LLC now owns 303 shares of the company’s stock valued at $102,000 after purchasing an additional 30 shares during the last quarter. CYBER HORNET ETFs LLC increased its holdings in Cencora by 6.8% during the 4th quarter. CYBER HORNET ETFs LLC now owns 485 shares of the company’s stock worth $164,000 after purchasing an additional 31 shares in the last quarter. Finally, Steph & Co. increased its holdings in Cencora by 23.5% during the 1st quarter. Steph & Co. now owns 168 shares of the company’s stock worth $53,000 after purchasing an additional 32 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Performance

COR stock opened at $318.54 on Thursday. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The firm has a market cap of $61.97 billion, a PE ratio of 24.43, a P/E/G ratio of 1.77 and a beta of 0.58. The business has a 50 day moving average of $287.66 and a 200-day moving average of $315.79. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. During the same quarter last year, the business posted $4.42 earnings per share. The business’s revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, sell-side analysts expect that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. Cencora’s dividend payout ratio (DPR) is currently 18.40%.

Cencora announced that its Board of Directors has approved a stock repurchase program on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 3.9% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Weiss Ratings lowered Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 30th. UBS Group upped their price target on Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Morgan Stanley set a $342.00 price objective on Cencora in a research note on Friday, May 8th. Barclays cut their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Finally, Evercore set a $360.00 target price on shares of Cencora in a research note on Wednesday, April 8th. Eleven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $367.75.

Insider Activity at Cencora

In other Cencora news, Director Lauren M. Tyler bought 550 shares of the stock in a transaction dated Monday, June 22nd. The shares were bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the purchase, the director directly owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.38% of the stock is owned by insiders.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.